Exploring Drug Safety Through Knowledge Graphs: Protein Kinase Inhibitors as a Case Study

• URL: http://arxiv.org/abs/2603.00097v1
• Date: Tue, 17 Feb 2026 12:30:33 GMT
• Title: Exploring Drug Safety Through Knowledge Graphs: Protein Kinase Inhibitors as a Case Study
• Abstract summary: Adverse Drug Reactions (ADRs) are a leading cause of morbidity and mortality.<n> Existing prediction methods rely mainly on chemical similarity, machine learning on structured databases, or isolated target profiles.<n>We present a knowledge graph-based framework that unifies diverse sources, drug-target data (EMBL), clinical trial literature (ChBL), trial metadata (ClinicalTrials.gov), and post-marketing safety reports (FAERS)<n>The resulting network enables contextual comparison of efficacy, phenotypic and target similarity, and ADR prediction via target-to-adverse-event correlations.
• Score: 3.487220175067471
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Adverse Drug Reactions (ADRs) are a leading cause of morbidity and mortality. Existing prediction methods rely mainly on chemical similarity, machine learning on structured databases, or isolated target profiles, but often fail to integrate heterogeneous, partly unstructured evidence effectively. We present a knowledge graph-based framework that unifies diverse sources, drug-target data (ChEMBL), clinical trial literature (PubMed), trial metadata (ClinicalTrials.gov), and post-marketing safety reports (FAERS) into a single evidence-weighted bipartite network of drugs and medical conditions. Applied to 400 protein kinase inhibitors, the resulting network enables contextual comparison of efficacy (HR, PFS, OS), phenotypic and target similarity, and ADR prediction via target-to-adverse-event correlations. A non-small cell lung cancer case study correctly highlights established and candidate drugs, target communities (ERbB, ALK, VEGF), and tolerability differences. Designed as an orthogonal, extensible analysis and search tool rather than a replacement for current models, the framework excels at revealing complex patterns, supporting hypothesis generation, and enhancing pharmacovigilance. Code and data are publicly available at https://github.com/davidjackson99/PKI_KG.

Related papers

• DrugReason: Dynamic Multi-View Reasoning over Knowledge Graph and Language Evidence for Drug Repurposing [55.45112712244231]
  DrugReason is a multi-view reasoning framework that integrates grounded KG reasoning with LLM-generated mechanistic inference for drug repurposing.<n> Experiments on PharmaDB, DDInter, and DrugBank show that DrugReason improves average performance over strong single-view reasoning baselines.
  arXiv  Detail & Related papers  (2026-09-06T18:54:26Z)
• Fairness Definitions and Metrics in Deep Reinforcement Learning for Drug Discovery in Healthcare: A Rapid Evidence Review [2.198430261120653]
  There is no concise synthesis of how fairness is defined, measured, and tested in DRL-based drug discovery.<n>We focus on three questions: (i) how dataset composition and split strategies, especially scaffold versus random splits, affect evaluation and distribution shift; (ii) how reward design (e.g., QED, docking, toxicity, synthetic accessibility) can create or mitigate bias, with emphasis on cancer targets; and (iii) which measurable metrics best capture fairness.
  arXiv  Detail & Related papers  (2026-06-01T21:18:27Z)
• Dual-Pathway Fusion of EHRs and Knowledge Graphs for Predicting Unseen Drug-Drug Interactions [5.481037938702276]
  Drug-drug interactions (DDIs) remain a major source of preventable harm.<n>We introduce, to our knowledge, the first system that conditions KG relation scoring on patient-level EHR context.<n>A fusion "Teacher" learns mechanism-specific relations for drug pairs represented in both sources.<n>A distilled "Student" generalizes to new or rarely used drugs without KG access at inference.
  arXiv  Detail & Related papers  (2025-11-10T03:18:16Z)
• A Hybrid Computational Intelligence Framework with Metaheuristic Optimization for Drug-Drug Interaction Prediction [0.8602553195689512]
  Drug-drug interactions (DDIs) are a leading cause of preventable adverse events, often complicating treatment and increasing healthcare costs.<n>We propose an interpretable and efficient framework that blends modern machine learning with domain knowledge to improve DDI prediction.<n>Our approach combines two complementary embeddings - Mol2Vec, which captures fragment-level structural patterns, and SMILES-BERT, which learns contextual chemical features.
  arXiv  Detail & Related papers  (2025-10-08T09:55:18Z)
• Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
  Conditional generation based on the target IC50 score can obtain a more effective sampling space. Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
  arXiv  Detail & Related papers  (2024-05-23T13:22:17Z)
• drGT: Attention-Guided Gene Assessment of Drug Response Utilizing a Drug-Cell-Gene Heterogeneous Network [8.664433151000255]
  drGT is a graph deep learning model that predicts sensitivity and aids in biomarker identification using attention coefficients (ACs)<n>The model is trained and evaluated using major benchmark datasets: Sanger GDSC, NCI60, and Broad CTRP, which cover a wide range of drugs and cancer cell lines.
  arXiv  Detail & Related papers  (2024-05-14T22:16:52Z)
• Multiscale Topology in Interactomic Network: From Transcriptome to Antiaddiction Drug Repurposing [0.3683202928838613]
  The escalating drug addiction crisis in the United States underscores the urgent need for innovative therapeutic strategies. This study embarked on an innovative and rigorous strategy to unearth potential drug repurposing candidates for opioid and cocaine addiction treatment.
  arXiv  Detail & Related papers  (2023-12-03T04:01:38Z)
• PGraphDTA: Improving Drug Target Interaction Prediction using Protein Language Models and Contact Maps [4.590060921188914]
  Key aspect of drug discovery involves identifying novel drug-target (DT) interactions. Protein-ligand interactions exhibit a continuum of binding strengths, known as binding affinity. We propose novel enhancements to enhance their performance.
  arXiv  Detail & Related papers  (2023-10-06T05:00:25Z)
• ADRNet: A Generalized Collaborative Filtering Framework Combining Clinical and Non-Clinical Data for Adverse Drug Reaction Prediction [49.56476929112382]
  Adverse drug reaction (ADR) prediction plays a crucial role in both health care and drug discovery. We propose ADRNet, a generalized collaborative filtering framework combining clinical and non-clinical data for drug-ADR prediction.
  arXiv  Detail & Related papers  (2023-08-03T11:28:12Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• CausalBench: A Large-scale Benchmark for Network Inference from Single-cell Perturbation Data [61.088705993848606]
  We introduce CausalBench, a benchmark suite for evaluating causal inference methods on real-world interventional data. CaulBench incorporates biologically-motivated performance metrics, including new distribution-based interventional metrics.
  arXiv  Detail & Related papers  (2022-10-31T13:04:07Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Modular multi-source prediction of drug side-effects with DruGNN [3.229607826010618]
  Drug Side-Effects (DSEs) have a high impact on public health, care system costs, and drug discovery processes. To predict their occurrence, it is necessary to integrate data from heterogeneous sources. In this work, such heterogeneous data is integrated into a graph dataset, expressively representing the relational information between different entities. Graph Neural Networks (GNNs) are exploited to predict DSEs on our dataset with very promising results.
  arXiv  Detail & Related papers  (2022-02-15T09:41:05Z)
• HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Data [56.53715632642495]
  Clinical trials face uncertain outcomes due to issues with efficacy, safety, or problems with patient recruitment. In this paper, we propose Hierarchical INteraction Network (HINT) for more general, clinical trial outcome predictions.
  arXiv  Detail & Related papers  (2021-02-08T15:09:07Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.